Dr. Amprey is founder of Zero Point Five Therapeutics. Previously he led scientific research at Symbiomix and helped with its first and second rounds of institutional funding. Prior to joining Symbiomix, he co-founded Zyngenia, an antibody-based drug development company focused on new therapeutics for breast cancer and autoimmune diseases. Before that, he ran the $300 million MedImmune Ventures, which is now part of AstraZeneca. Dr. Amprey also worked at Carrot Capital, where he was responsible for deal sourcing and had operational roles within their portfolio of companies. He also completed his internship in internal medicine through a joint residency training program at both New York-Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. Dr. Amprey earned his bachelor’s degree in biochemistry from the University of Pennsylvania and his doctorate of immunology and medical degree from Cornell University.